Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant SHR-1210 and Radiation in Resectable ESCC
NCT03200691Phase 2Unknown
- Start
- Aug 2017
- Primary completion
- Jun 2018
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in Esophageal Squamous Cell Carcinoma (ESCC). Status: unknown.
02
Drugs
camrelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03200691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03200691.